Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| ABBOTT LABORATORIESABT · Entity 2314 | Executive Vice President | April 23, 2019 | April 24, 2019 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
ABBOTT LABORATORIES
Report date April 23, 2019 · Filed April 24, 2019
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common shares without par valueSEC Table I · non-derivative | Direct | 169,935 |
Ending reported balance
After 2019-04-23 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2019-04-23 · Exercise / conversion · Acquired 56,000 · Balance 225,935 Row 2 · 2019-04-23 · Sale · Disposed 56,000 · Balance 169,935 |
| Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $47.00 · Expires 2025-02-19 | Direct | 113,227 |
Reported balance
After 2019-04-23 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2019-04-23 · Exercise / conversion · Disposed 56,000 · Balance 113,227 F3: Employee stock option granted pursuant to the Abbott Laboratories 2009 Incentive Stock Program, in a transaction exempt from Section 16 under Rule 16b-3. |
| Common shares without par valueSEC Table I · non-derivative | IndirectProfit Sharing Trust | 1,698 |
Reported balance
Holding disclosure · report date 2019-04-23 · row 3
Holding and transaction disclosures are not merged.
1 source rowRow 3 · Balance 1,698 F1: Balance in the Abbott Laboratories Stock Retirement Trust as of April 23, 2019. |
| Common shares without par valueSEC Table I · non-derivative | IndirectBy Spouse | 53 |
Reported balance
Holding disclosure · report date 2019-04-23 · row 4
Holding and transaction disclosures are not merged.
1 source rowRow 4 · Balance 53 F2: The reporting person disclaims beneficial ownership of all securities held by his spouse. |
Filing footnotes · ownership attribution and instrument terms
F1: Balance in the Abbott Laboratories Stock Retirement Trust as of April 23, 2019.
F2: The reporting person disclaims beneficial ownership of all securities held by his spouse.
F3: Employee stock option granted pursuant to the Abbott Laboratories 2009 Incentive Stock Program, in a transaction exempt from Section 16 under Rule 16b-3.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| February 20, 2018 Filed Feb 22, 2018 00:23 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | SaleCommon shares without par value | 3,419 | $59.76 | $204,319.44 |
DisclosureSEC source: 0001179110-18-002537 · edgar.xml · nonDerivative · entry 19 Fussell Stephen R · CIK 0001327700 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 199,860 Read SEC document |
| February 20, 2018 Filed Feb 22, 2018 00:23 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | SaleCommon shares without par value | 1,700 | $59.76 | $101,583.50 |
DisclosureSEC source: 0001179110-18-002537 · edgar.xml · nonDerivative · entry 18 Fussell Stephen R · CIK 0001327700 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 203,279 Read SEC document |
| February 20, 2018 Filed Feb 22, 2018 00:23 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | SaleCommon shares without par value | 3,100 | $59.75 | $185,225.00 |
DisclosureSEC source: 0001179110-18-002537 · edgar.xml · nonDerivative · entry 17 Fussell Stephen R · CIK 0001327700 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 204,979 Read SEC document |
| February 20, 2018 Filed Feb 22, 2018 00:23 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | SaleCommon shares without par value | 106 | $59.75 | $6,332.97 |
DisclosureSEC source: 0001179110-18-002537 · edgar.xml · nonDerivative · entry 16 Fussell Stephen R · CIK 0001327700 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 208,079 Read SEC document |
| February 20, 2018 Filed Feb 22, 2018 00:23 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | SaleCommon shares without par value | 600 | $59.74 | $35,844.00 |
DisclosureSEC source: 0001179110-18-002537 · edgar.xml · nonDerivative · entry 15 Fussell Stephen R · CIK 0001327700 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 208,185 Read SEC document |
| February 20, 2018 Filed Feb 22, 2018 00:23 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | SaleCommon shares without par value | 116 | $59.74 | $6,929.26 |
DisclosureSEC source: 0001179110-18-002537 · edgar.xml · nonDerivative · entry 14 Fussell Stephen R · CIK 0001327700 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 208,785 Read SEC document |
| February 20, 2018 Filed Feb 22, 2018 00:23 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | SaleCommon shares without par value | 1,600 | $59.73 | $95,568.00 |
DisclosureSEC source: 0001179110-18-002537 · edgar.xml · nonDerivative · entry 13 Fussell Stephen R · CIK 0001327700 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 208,901 Read SEC document |
| February 20, 2018 Filed Feb 22, 2018 00:23 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | SaleCommon shares without par value | 100 | $59.73 | $5,972.75 |
DisclosureSEC source: 0001179110-18-002537 · edgar.xml · nonDerivative · entry 12 Fussell Stephen R · CIK 0001327700 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 210,501 Read SEC document |
| February 20, 2018 Filed Feb 22, 2018 00:23 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | SaleCommon shares without par value | 628 | $59.73 | $37,507.30 |
DisclosureSEC source: 0001179110-18-002537 · edgar.xml · nonDerivative · entry 11 Fussell Stephen R · CIK 0001327700 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 210,601 Read SEC document |
| February 20, 2018 Filed Feb 22, 2018 00:23 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | SaleCommon shares without par value | 1,294 | $59.72 | $77,277.68 |
DisclosureSEC source: 0001179110-18-002537 · edgar.xml · nonDerivative · entry 10 Fussell Stephen R · CIK 0001327700 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 211,229 Read SEC document |
| February 20, 2018 Filed Feb 22, 2018 00:23 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | SaleCommon shares without par value | 2,900 | $59.71 | $173,159.00 |
DisclosureSEC source: 0001179110-18-002537 · edgar.xml · nonDerivative · entry 9 Fussell Stephen R · CIK 0001327700 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 212,523 Read SEC document |
| February 20, 2018 Filed Feb 22, 2018 00:23 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | SaleCommon shares without par value | 200 | $59.71 | $11,941.00 |
DisclosureSEC source: 0001179110-18-002537 · edgar.xml · nonDerivative · entry 8 Fussell Stephen R · CIK 0001327700 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 215,423 Read SEC document |
| February 20, 2018 Filed Feb 22, 2018 00:23 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | SaleCommon shares without par value | 1,900 | $59.70 | $113,430.00 |
DisclosureSEC source: 0001179110-18-002537 · edgar.xml · nonDerivative · entry 7 Fussell Stephen R · CIK 0001327700 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 215,623 Read SEC document |
| February 20, 2018 Filed Feb 22, 2018 00:23 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | SaleCommon shares without par value | 901 | $59.70 | $53,785.20 |
DisclosureSEC source: 0001179110-18-002537 · edgar.xml · nonDerivative · entry 6 Fussell Stephen R · CIK 0001327700 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 217,523 Read SEC document |
| February 20, 2018 Filed Feb 22, 2018 00:23 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | SaleCommon shares without par value | 2,300 | $59.69 | $137,287.00 |
DisclosureSEC source: 0001179110-18-002537 · edgar.xml · nonDerivative · entry 5 Fussell Stephen R · CIK 0001327700 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 218,424 Read SEC document |
| February 20, 2018 Filed Feb 22, 2018 00:23 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | SaleCommon shares without par value | 2,999 | $59.69 | $178,995.32 |
DisclosureSEC source: 0001179110-18-002537 · edgar.xml · nonDerivative · entry 4 Fussell Stephen R · CIK 0001327700 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 220,724 Read SEC document |
| February 20, 2018 Filed Feb 22, 2018 00:23 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | SaleCommon shares without par value | 2,774 | $59.68 | $165,552.32 |
DisclosureSEC source: 0001179110-18-002537 · edgar.xml · nonDerivative · entry 3 Fussell Stephen R · CIK 0001327700 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 223,723 Read SEC document |
| February 20, 2018 Filed Feb 22, 2018 00:23 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | SaleCommon shares without par value | 600 | $59.68 | $35,805.00 |
DisclosureSEC source: 0001179110-18-002537 · edgar.xml · nonDerivative · entry 2 Fussell Stephen R · CIK 0001327700 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 226,497 Read SEC document |
| February 20, 2018 Filed Feb 22, 2018 00:23 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | SaleCommon shares without par value | 6,028 | $59.67 | $359,690.76 |
DisclosureSEC source: 0001179110-18-002537 · edgar.xml · nonDerivative · entry 1 Fussell Stephen R · CIK 0001327700 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 227,097 Read SEC document |
| February 20, 2018 Filed Feb 22, 2018 00:24 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | SaleCommon shares without par value | 900 | $59.86 | $53,874.00 |
DisclosureSEC source: 0001179110-18-002538 · edgar.xml · nonDerivative · entry 7 Fussell Stephen R · CIK 0001327700 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 184,884 Read SEC document |
| February 20, 2018 Filed Feb 22, 2018 00:24 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | SaleCommon shares without par value | 100 | $59.86 | $5,985.75 |
DisclosureSEC source: 0001179110-18-002538 · edgar.xml · nonDerivative · entry 6 Fussell Stephen R · CIK 0001327700 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 185,784 Read SEC document |
| February 20, 2018 Filed Feb 22, 2018 00:24 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | SaleCommon shares without par value | 400 | $59.86 | $23,942.00 |
DisclosureSEC source: 0001179110-18-002538 · edgar.xml · nonDerivative · entry 5 Fussell Stephen R · CIK 0001327700 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 185,884 Read SEC document |
| February 20, 2018 Filed Feb 22, 2018 00:24 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | SaleCommon shares without par value | 1,000 | $59.85 | $59,850.00 |
DisclosureSEC source: 0001179110-18-002538 · edgar.xml · nonDerivative · entry 4 Fussell Stephen R · CIK 0001327700 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 186,284 Read SEC document |
| February 20, 2018 Filed Feb 22, 2018 00:24 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | SaleCommon shares without par value | 1,100 | $59.84 | $65,824.00 |
DisclosureSEC source: 0001179110-18-002538 · edgar.xml · nonDerivative · entry 3 Fussell Stephen R · CIK 0001327700 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 187,284 Read SEC document |
| February 20, 2018 Filed Feb 22, 2018 00:24 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | SaleCommon shares without par value | 1,832 | $59.83 | $109,608.56 |
DisclosureSEC source: 0001179110-18-002538 · edgar.xml · nonDerivative · entry 2 Fussell Stephen R · CIK 0001327700 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 188,384 Read SEC document |
| February 20, 2018 Filed Feb 22, 2018 00:24 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | SaleCommon shares without par value | 200 | $59.82 | $11,964.00 |
DisclosureSEC source: 0001179110-18-002538 · edgar.xml · nonDerivative · entry 1 Fussell Stephen R · CIK 0001327700 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 190,216 Read SEC document |
| February 16, 2018 Filed Feb 22, 2018 00:23 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | GrantOption (right to buy) · Derivative | 246,963 | $0.00 Strike: $59.94 | $0.00 |
DisclosureSEC source: 0001179110-18-002536 · edgar.xml · derivative · entry 31 Fussell Stephen R · CIK 0001327700 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 246,963 Underlying: Common shares · 246,963 shares Expires 2028-02-15 F2 · security: Employee stock option granted pursuant to the Abbott Laboratories 2017 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. The option becomes exercisable in annual increments of 82,321 on 02/16/2019, 82,321 on 02/16/2020, and 82,321 on 02/16/2021. Read SEC document |
| February 16, 2018 Filed Feb 22, 2018 00:23 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | GrantCommon shares without par value | 44,909 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-18-002536 · edgar.xml · nonDerivative · entry 1 Fussell Stephen R · CIK 0001327700 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 184,884 F1 · shares: These shares represent performance vested restricted stock awards under the Abbott Laboratories 2017 Incentive Stock Program. The awards have a 3-year term, with no more than 1/3 of the award vesting in any one year upon Abbott reaching a minimum return on equity target. The awards include the right to have stock withheld for tax purposes. Read SEC document |
| January 31, 2018 Filed Feb 1, 2018 22:48 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | SaleCommon shares without par value | 1,000 | $62.68 | $62,680.00 |
DisclosureSEC source: 0001179110-18-001374 · edgar.xml · nonDerivative · entry 9 Fussell Stephen R · CIK 0001327700 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 561,518 Read SEC document |
| January 30, 2018 Filed Feb 1, 2018 22:48 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | Exercise / conversionOption (right to buy) · Derivative | 104,642 | $0.00 Strike: $38.40 | $0.00 |
DisclosureSEC source: 0001179110-18-001374 · edgar.xml · derivative · entry 33 Fussell Stephen R · CIK 0001327700 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 209,284 Underlying: Common shares · 104,642 shares Expires 2026-02-18 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: Employee stock option granted pursuant to the Abbott Laboratories 2009 Incentive Stock Program, in a transaction exempt from Section 16 under Rule 16b-3. Read SEC document |
| January 30, 2018 Filed Feb 1, 2018 22:48 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | Exercise / conversionOption (right to buy) · Derivative | 134,741 | $0.00 Strike: $39.12 | $0.00 |
DisclosureSEC source: 0001179110-18-001374 · edgar.xml · derivative · entry 32 Fussell Stephen R · CIK 0001327700 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common shares · 134,741 shares Expires 2024-02-20 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: Employee stock option granted pursuant to the Abbott Laboratories 2009 Incentive Stock Program, in a transaction exempt from Section 16 under Rule 16b-3. Read SEC document |
| January 30, 2018 Filed Feb 1, 2018 22:48 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | Exercise / conversionOption (right to buy) · Derivative | 149,600 | $0.00 Strike: $34.94 | $0.00 |
DisclosureSEC source: 0001179110-18-001374 · edgar.xml · derivative · entry 31 Fussell Stephen R · CIK 0001327700 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common shares · 149,600 shares Expires 2023-02-14 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: Employee stock option granted pursuant to the Abbott Laboratories 2009 Incentive Stock Program, in a transaction exempt from Section 16 under Rule 16b-3. Read SEC document |
| January 30, 2018 Filed Feb 1, 2018 22:48 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | SaleCommon shares without par value | 32,143 | $62.78 | $2,017,937.54 |
DisclosureSEC source: 0001179110-18-001374 · edgar.xml · nonDerivative · entry 30 Fussell Stephen R · CIK 0001327700 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 343,709 Read SEC document |
| January 30, 2018 Filed Feb 1, 2018 22:48 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | SaleCommon shares without par value | 800 | $62.78 | $50,222.00 |
DisclosureSEC source: 0001179110-18-001374 · edgar.xml · nonDerivative · entry 29 Fussell Stephen R · CIK 0001327700 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 375,852 Read SEC document |
| January 30, 2018 Filed Feb 1, 2018 22:48 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | SaleCommon shares without par value | 1,328 | $62.78 | $83,365.20 |
DisclosureSEC source: 0001179110-18-001374 · edgar.xml · nonDerivative · entry 28 Fussell Stephen R · CIK 0001327700 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 376,652 Read SEC document |
| January 30, 2018 Filed Feb 1, 2018 22:48 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | SaleCommon shares without par value | 6,986 | $62.77 | $438,511.22 |
DisclosureSEC source: 0001179110-18-001374 · edgar.xml · nonDerivative · entry 27 Fussell Stephen R · CIK 0001327700 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 377,980 Read SEC document |
| January 30, 2018 Filed Feb 1, 2018 22:48 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | SaleCommon shares without par value | 800 | $62.77 | $50,214.00 |
DisclosureSEC source: 0001179110-18-001374 · edgar.xml · nonDerivative · entry 26 Fussell Stephen R · CIK 0001327700 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 384,966 Read SEC document |
| January 30, 2018 Filed Feb 1, 2018 22:48 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | SaleCommon shares without par value | 4,886 | $62.77 | $306,669.79 |
DisclosureSEC source: 0001179110-18-001374 · edgar.xml · nonDerivative · entry 25 Fussell Stephen R · CIK 0001327700 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 385,766 Read SEC document |
| January 30, 2018 Filed Feb 1, 2018 22:48 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | SaleCommon shares without par value | 3,703 | $62.76 | $232,400.28 |
DisclosureSEC source: 0001179110-18-001374 · edgar.xml · nonDerivative · entry 24 Fussell Stephen R · CIK 0001327700 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 390,652 Read SEC document |
| January 30, 2018 Filed Feb 1, 2018 22:48 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | SaleCommon shares without par value | 4,724 | $62.76 | $296,454.62 |
DisclosureSEC source: 0001179110-18-001374 · edgar.xml · nonDerivative · entry 23 Fussell Stephen R · CIK 0001327700 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 394,355 Read SEC document |
| January 30, 2018 Filed Feb 1, 2018 22:48 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | SaleCommon shares without par value | 53,383 | $62.75 | $3,349,783.25 |
DisclosureSEC source: 0001179110-18-001374 · edgar.xml · nonDerivative · entry 22 Fussell Stephen R · CIK 0001327700 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 399,079 Read SEC document |
| January 30, 2018 Filed Feb 1, 2018 22:48 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | SaleCommon shares without par value | 2,615 | $62.75 | $164,084.71 |
DisclosureSEC source: 0001179110-18-001374 · edgar.xml · nonDerivative · entry 21 Fussell Stephen R · CIK 0001327700 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 452,462 Read SEC document |
| January 30, 2018 Filed Feb 1, 2018 22:48 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | SaleCommon shares without par value | 83,546 | $62.75 | $5,242,093.77 |
DisclosureSEC source: 0001179110-18-001374 · edgar.xml · nonDerivative · entry 20 Fussell Stephen R · CIK 0001327700 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 455,077 Read SEC document |
| January 30, 2018 Filed Feb 1, 2018 22:48 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | SaleCommon shares without par value | 8,400 | $62.74 | $527,016.00 |
DisclosureSEC source: 0001179110-18-001374 · edgar.xml · nonDerivative · entry 19 Fussell Stephen R · CIK 0001327700 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 538,623 Read SEC document |
| January 30, 2018 Filed Feb 1, 2018 22:48 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | SaleCommon shares without par value | 4,017 | $62.74 | $252,006.50 |
DisclosureSEC source: 0001179110-18-001374 · edgar.xml · nonDerivative · entry 18 Fussell Stephen R · CIK 0001327700 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 547,023 Read SEC document |
| January 30, 2018 Filed Feb 1, 2018 22:48 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | SaleCommon shares without par value | 5,903 | $62.73 | $370,295.19 |
DisclosureSEC source: 0001179110-18-001374 · edgar.xml · nonDerivative · entry 17 Fussell Stephen R · CIK 0001327700 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 551,040 Read SEC document |
| January 30, 2018 Filed Feb 1, 2018 22:48 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | SaleCommon shares without par value | 3,010 | $62.73 | $188,802.25 |
DisclosureSEC source: 0001179110-18-001374 · edgar.xml · nonDerivative · entry 16 Fussell Stephen R · CIK 0001327700 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 556,943 Read SEC document |
| January 30, 2018 Filed Feb 1, 2018 22:48 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | SaleCommon shares without par value | 9 | $62.72 | $564.44 |
DisclosureSEC source: 0001179110-18-001374 · edgar.xml · nonDerivative · entry 15 Fussell Stephen R · CIK 0001327700 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 559,953 Read SEC document |
| January 30, 2018 Filed Feb 1, 2018 22:48 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | SaleCommon shares without par value | 100 | $62.71 | $6,271.00 |
DisclosureSEC source: 0001179110-18-001374 · edgar.xml · nonDerivative · entry 14 Fussell Stephen R · CIK 0001327700 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 559,962 Read SEC document |
| January 30, 2018 Filed Feb 1, 2018 22:48 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | SaleCommon shares without par value | 500 | $62.71 | $31,352.50 |
DisclosureSEC source: 0001179110-18-001374 · edgar.xml · nonDerivative · entry 13 Fussell Stephen R · CIK 0001327700 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 560,062 Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.